BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
Negative
AI Analysis
Summary
BioXcel Therapeutics has filed for Chapter 11 bankruptcy with Teva Pharmaceuticals serving as the stalking horse bidder to acquire its AI-derived assets for up to $125 million through an auction process.
Outcome Details
BioXcel filing Chapter 11 bankruptcy with Teva as stalking horse bidder for AI-derived assets
Importance:8/10
Sentiment:
-0.90
bankruptcyacquisitionasset saleChapter 11AI therapeutics
Read the original article
Published by BioSpace on August 28, 2026 3:04 PM